Search clinical trials for: Deferasirox and Deferoxamine

Total 269722 results

Novartis Pharmaceuticals

Completed

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload (CORDELIA)

Transfusional Hemosiderosis | Transfusional Iron Overload

Taiwan, Turkey, Egypt, United Kingdom, Thailand, Canada, China, Italy, Cyprus, Lebanon, United Arab Emirates
Elliott Vichinsky

Completed

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Iron Overload | Thalassemia

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload (HYPERION)

Cardiac Iron Overload

Taiwan, Egypt, Thailand, Turkey, United Kingdom, Italy, Canada, Greece
Novartis Pharmaceuticals

Completed

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Anemia, Sickle Cell

United States
Novartis Pharmaceuticals

Completed

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Iron Overload | Sickle Cell Disease | Hemolytic Anemia

United States, Canada
Hormozgan University of Medical Sciences

Completed

Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload

Iron Overload | Thalassemia | Transfusion Related Complications

Iran, Islamic Republic of
Novartis Pharmaceuticals

Completed

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Beta-Thalassemia

United States
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

Cardiac Iron Overload | Transfusion-dependent β-thalassemia Patients

Greece
Brigham and Women's Hospital
National Institute on Aging (NIA)

Completed

Modulation of Cerebral Blood Flow Using Iron Chelators (DFO)

Stroke | Problem of Aging

United States
Weill Medical College of Cornell University

Unknown

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

Thalassemia

United States
Boston Children's Hospital
Novartis

Completed

Pilot Study for Patients With Poor Response to Deferasirox

Sickle Cell Disease | Thalassemia Major | Transfusion-dependent Hemachromatosis

United States
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Terminated

Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
Brigham and Women's Hospital
Dr. Jeffrey Thomas Stroke Shield Foundation

Terminated

Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Subarachnoid Hemorrhage

United States
Beth Israel Deaconess Medical Center
Medical University of South Carolina; Johns Hopkins University; Massachusetts... and other collaborators

Completed

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Intracerebral Hemorrhage

United States, Canada
Memorial Sloan Kettering Cancer Center
Center for Experimental Therapeutics; F.M. KIRBY FOUNDATION

Recruiting

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Leptomeningeal Metastases

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

Hematologic Diseases | Iron Overload | Hemoglobinopathies | Thalassemia | Beta-Thalassemia | Hemochromatosis | Anemia (Iron-Loading)
Beth Israel Deaconess Medical Center
Medical University of South Carolina; Massachusetts General Hospital; National... and other collaborators

Completed

Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage (DFO In ICH)

Intracerebral Hemorrhage

United States
Capital Medical University
Peking University First Hospital; Peking University People's Hospital; Beijing... and other collaborators

Unknown

Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage

Intracerebral Hemorrhage

China
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Transfusion-dependent Anemia

Egypt, Hungary, Turkey, United States, Bulgaria, Italy, Belgium, Russian Federation, Philippines, France, Malaysia, India, Oman, Panama, Lebanon, Thailand, Tunisia
Novartis Pharmaceuticals

Completed

Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet (Jupiter)

Non-transfusion-dependent Thalassemia | Transfusion-dependent Thalassemia

Egypt, Turkey, Thailand, Lebanon, Morocco, Saudi Arabia, Vietnam
TauTona Group

Withdrawn

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment (D-SCOUT)

Sickle Cell Disease | Chronic Cutaneous Ulcer

United States
DisperSol Technologies, LLC

Completed

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

Thalassemia Major

Thailand, United States
Novartis Pharmaceuticals

Withdrawn

Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia (CENTAurus)

Thalassemia (Transfusion Delendent)
Assistance Publique - Hôpitaux de Paris
Association pour l'Etude des Fonctions Digestives (AEFD)

Unknown

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

Porphyria Cutanea Tarda

France
Novartis

Completed

A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Beta-Thalassemia | Hemosiderosis

Egypt, Lebanon, Oman, Saudi Arabia, Syrian Arab Republic
Novartis Pharmaceuticals

Completed

Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

Low and Int 1-risk Myelodysplastic Syndrome

Germany, Canada, Korea, Republic of, Sweden, Spain, China, Argentina, Italy, United Kingdom, Algeria
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia (THETIS)

Non-transfusion Dependent Thalassemia

Thailand, Turkey, Italy, Greece, China, United Kingdom, Lebanon, Tunisia
City of Hope Medical Center

Terminated

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Iron Overload | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditions

United States
Crolll Gmbh
University of Magdeburg; Estimate, GmbH

Completed

The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (DEFINE)

Non-alcoholic Steatohepatitis | Increased Iron Storage / Disturbed Distribution

Germany
Ain Shams University

Unknown

Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)

Beta-thalassemia | Serum Ferritin | Iron Chelation Therapy

Egypt
Novartis Pharmaceuticals

Completed

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Transfusional Hemosiderosis

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Iron Overload | Hereditary Hemochromatosis

United States, Germany, Italy, Australia, Canada, France
Masonic Cancer Center, University of Minnesota

Terminated

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Breast Cancer | Iron Overload | Ovarian Cancer | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Novartis Pharmaceuticals

Completed

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Myelodysplastic Syndromes | Beta-Thalassemia

Hungary
Ospedale Microcitemico
Azienda Sanitaria Locale di Cagliari

Completed

Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major (DFODFPTM)

Iron Overload | Cardiomyopathy

Italy
Academisch Medisch Centrum - Universiteit van Amsterdam...

Completed

Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease (TROS)

Sickle Cell Disease

Netherlands
Abramson Cancer Center of the University of Pennsylvania

Completed

Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

High Risk MDS or AML Patients

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

Myelodysplastic Syndromes | Transfusion Dependent Iron Overload

Germany
Novartis

Completed

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Myelodysplastic Syndromes | Hemoglobinopathies | Diamond-Blackfan Anemia | Transfusional Iron Overload | Other Inherited or Acquired Anaemia | MPD Syndrome | Other Rare Anaemias

Australia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Transfusional Hemosiderosis | Chronic Anemia

Japan, Turkey, Spain, Poland, Singapore
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study (THALASSA)

Non-transfusion Dependent Thalassemia

Greece, Taiwan, Italy, United Kingdom, Lebanon, Turkey, Malaysia, Thailand, United States
Children's Hospital Los Angeles
Novartis Pharmaceuticals

Terminated

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

Anemia, Sickle Cell | Transfusion Hemosiderosis

United States
Novartis Pharmaceuticals

Completed

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Transfusional Hemosiderosis

Egypt, Spain, United Kingdom, Jordan
Genzyme, a Sanofi Company

Completed

Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia

Beta-Thalassemia

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia

Iron Overload

China
Novartis Pharmaceuticals

Completed

Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload

Iron Overload

Spain
Children's Hospital of Philadelphia
Ann & Robert H Lurie Children's Hospital of Chicago; The Cooley's Anemia Foundation...

Completed

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

Thalassemia Major With Severe Transfusional Iron Overload

United States
Sun Yat-sen University

Recruiting

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer

China
ApoPharma

Completed

Efficacy Study in Removing Excess Iron From the Heart

Hemosiderosis | Thalassemia Major

Greece, Italy
Jinan Military General Hospital

Recruiting

The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable

China

Search clinical trials for: Deferasirox and Deferoxamine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations